Week Ending November 29, 2021

FDA unlocks faster clearances for future hepatitis C diagnostics
“The FDA has eased up on makers of new diagnostic tests for hepatitis C, granting them a quicker pathway to the market.”

Liver cancer can be recognized by RNA fragments in saliva and blood
“RUDN University doctors examined markers of liver cancer and found that the disease can be recognized by RNA fragments in saliva and blood. The results are published in Oncotarget.”

Antiviral treatment for hepatitis C virus reduces risk of post-treatment liver cancer progression
“In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease with a high recurrence rate, researchers at the Osaka City University Graduate School of Medicine reported that after receiving cancer treatment, the oral administration of direct-acting antivirals (DAA) reduces the risk of tumor progression following recurrence of the liver disease. The findings were published in the Journal of Viral Hepatitis.”

COVID slowed Louisiana’s ‘Netflix model’ for eliminating hepatitis C. Is there time to catch up?
“In July 2019, Louisiana health officials brokered an unprecedented deal: For $58 million yearly for up to five years, the state would have unlimited access to a $24,000 hepatitis C drug for Medicaid patients and the prison population.”

New York State Department of Health Announces Release of Hepatitis C Elimination Plan
“The New York State Department of Health today released the New York State Hepatitis C Elimination Plan. These recommendations were developed by the Hepatitis C Elimination Task Force in collaboration with community-based organizations, health care providers, harm reduction specialists, social service providers and public health professionals. The Hepatitis C Elimination Plan focuses on five key areas to reach those most at-risk:”